卵巢外腹膜浆液性乳头状癌5例报告

目的报告5例卵巢外浆液性乳头状癌(EPSPC)并观察其临床病理特点.方法对1995年4月～1999年3月在我院治疗5例EPSPC的临床资料进行回顾性分析.结果5例术前均行PAC方案化疗2～4疗程,然后行手术治疗,其中2例残留肿瘤＜2cm,术后再行PAC方案化疗,进行随访,1例化疗6个疗程后,生存1年8个月,1例9月后复发,1例仅行活检6月死亡;残留肿瘤＞2cm 2例,预后差..结论对EPSPC患者应施行肿瘤细胞减灭术及PAC方案化疗,残留肿瘤＜2cm者预后较好.     

卵巢外腹膜浆液性乳头状癌四例临床分析

卵巢外腹膜浆液性乳头状癌 (ＥＰＳＰＣ)是最常见的原发性腹膜苗勒氏上皮癌。国内自 1996年始对ＥＰＳＰＣ已有了报道[2 ] ,但在近年的相关报道中 ,该病名称仍未统一。我院1995年 1月～ 2 0 0 1年 8月收治 4例ＥＰＳＰＣ患者 ,现报告如下 ,并就其临床特点、诊治及预后进行分析 ,旨在统一名称下 ,提高对ＥＰＳＰＣ的诊治水平。一、临床资料1 一般资料 :4例ＥＰＳＰＣ患者的年龄分别为 4 9,5 5 ,5 6和6 2岁 ,均已婚已育 ,其中 3人已绝经。病程 1～ 3个月 ,主诉均为进行性腹胀 ,食欲减退 ,腹围增大 ,体重减轻。其中有1例伴双侧锁骨上及两侧腹股…     

卵巢外腹膜乳头状浆液性腺癌九例临床分析

对1995年1月～2002年12月本院收治的9例卵巢外腹膜乳头状浆液性腺癌的临床资料进行回顾性分析，其诊断均经病理学证实。所有病例均无特异性症状，术前无1例确诊(误诊率100％)。9例患者均为腹盆腔广泛种植的乳头状浆液性腺癌，3例病变累及卵巢表面。2例仅行肿瘤活检术，术后放弃化疗，分别存活3个月和7个月；7例行肿瘤减灭术后均接受6～8个疗程的CP/CAP方案化疗(C：环磷酰胺、A：多柔比星／表阿霉素、P：顺铂)，生存9～47个月。9例患者平均生存24个月。     

卵巢外腹膜浆液性乳头状癌5例报告

目的:报告5例卵巢外浆液性乳头状癌(EPSPC)并观察其临床病理特点.方法:对1995年4月～1999年3月在我院治疗5例EPSPC的临床资料进行回顾性分析.结果:5例术前均行PAC方案化疗2～4疗程,然后行手术治疗,其中2例残留肿瘤＜2cm,术后再行PAC方案化疗,进行随访,1例化疗6个疗程后,生存1年8个月,1例9月后复发,1例仅行活检6月死亡;残留肿瘤＞2cm 2例,预后差..结论:对EPSPC患者应施行肿瘤细胞减灭术及PAC方案化疗,残留肿瘤＜2cm者预后较好.     

卵巢外腹膜乳头状浆液性腺癌九例临床分析

对 1995年 1月～ 2 0 0 2年 12月本院收治的 9例卵巢外腹膜乳头状浆液性腺癌的临床资料进行回顾性分析 ,其诊断均经病理学证实。所有病例均无特异性症状 ,术前无 1例确诊 (误诊率 10 0 % )。 9例患者均为腹盆腔广泛种植的乳头状浆液性腺癌 ,3例病变累及卵巢表面。 2例仅行肿瘤活检术 ,术后放弃化疗 ,分别存活 3个月和 7个月 ;7例行肿瘤减灭术后均接受 6～ 8个疗程的CP/CAP方案化疗 (C :环磷酰胺、A :多柔比星 /表阿霉素、P :顺铂 ) ,生存 9～ 47个月。 9例患者平均生存 2 4个月     

卵巢外腹膜浆液性乳头状癌6例分析

目的分析卵巢外腹膜浆液性乳头状癌(EPSPC)的临床特点，鉴别诊断及治疗。方法对1999年11月—2004年9月我科收治的6例EPSPC病人的临床资料进行回顾性分析。结果经采用卵巢肿瘤细胞减灭术及全身化疗(PAC、TP方案)4—9疗程，6例中3例存活，2例死亡，1例失访。结论根据病史，临床表现与相关检查，EPSPC的术前诊断是可能的，该病预后较差。肿瘤细胞减灭术和全身化疗可改善预后。CA125可做为诊断及治疗监测指标之一。     

卵巢外腹膜浆液性乳头状癌26例临床病理研究

卵巢外腹膜浆液性乳头状癌 (ＥＰＳＰＣ)是原发于腹膜表面的、双侧卵巢正常或表面有微小侵袭的、组织学形态与卵巢浆液性乳头状癌 (ＰＳＣＯ)相似的恶性肿瘤。以往学者们认为 ,ＥＰＳＰＣ类似卵巢癌Ⅲｃ 期、腹膜恶性间皮瘤。我们通过肿瘤组织特殊染色和特殊抗原标记 ,对ＥＰＳＰＣ临床病理特点进行分析。一、资料与方法1 临床资料 :1990年 1月～ 2 0 0 0年 6月间 ,我院收治卵巢癌 32 1例 ,其中ＥＰＳＰＣ 2 6例。发病年龄 42～ 6 9岁 ,平均年龄 5 6 .7岁。患者均无家族史 ,无石棉、滑石粉等有害物质接触史。患者有下腹坠痛和腹围增长快。Ｂ…     

卵巢外腹膜浆液性乳头状癌的临床诊断与治疗

目的：探讨卵巢外腹膜浆液性乳头状癌(EPSPC)的临床诊断与治疗。方法：对1989年1月～2003年3月收治的、经病理检查证实的9例EPSPC的临床资料进行回顾性分析。结果：经采用肿瘤细胞减灭术及术后PC或PAC方案8个疗程的治疗，9例患中，除1例为术后1个月，4例失访，3例死亡，1例无瘤生存4年。结论：根据病史、临床表现与相关检查，EPSPC的术前诊断是可能的；肿瘤细胞减灭术与术后化疗可改善预后。     

卵巢外腹膜浆液性乳头状癌临床特征、治疗及预后(附11例分析)

背景与目的: 卵巢外腹膜浆液性乳头状癌(extraovarian peritoneal serous papillary carcinoma,EPSPC)是原发于腹膜间皮,有时可累及卵巢表面,呈多灶性发生的恶性肿瘤,发病率低,近年来逐渐引起人们的重视,目前暂无标准的治疗方案.本文分析11例EPSPC,初步探讨其临床特征、治疗及预后.方法: 回顾性分析11例EPSPC临床特征,采用肿瘤细胞减灭术及术后辅助化疗进行综合治疗,最后采用RECIST评价近期疗效,进展时间(TTP)及总生存率评价远期疗效.结果: EPSPC患者临床表现均为腹痛,进行性加重腹胀、腹水,但仅有18.2%可体检查出腹部包块,腹水阳性率为100%.腹部B超、MRI扫描发现腹部包块的阳性率分别为45.5%、100%,血浆、腹水CA125升高>300 U/ml(正常<35 U/m1)的比率分别为72.7%(8/11)、81.8%(9/11).EPSPC,患者肿瘤细胞减灭术的成功率为45.5%.化疗完全缓解1例(11.1%,1/9),部分缓解3例(33.3%,3/9),稳定2例(22.2%,2/9),进展3例(33.3%,3/9),化疗有效率为4例(44.4%,4/9).TTP为5～14个月,中位TTP为8.6个月,1、2、3年生存率分别为72.7%(8/11)、18.2%(2/11)和0%(0/11),中位生存期14.6个月.结论: EPSPC临床症状无特异,腹水癌细胞检查、腹部MRI以及血浆与腹水CA125的表达水平对诊断EPSPC最具有临床意义.EPSPC肿瘤细胞减灭术的成功率低,对化疗抗拒,预后极差.     

卵巢外腹膜浆液性乳头状癌与卵巢浆液性乳头状癌比较分析

目的　探讨卵巢外原发腹膜浆液性乳头状癌 (EPSPC)的临床和治疗特点及预后。方法回顾性分析 12例EPSPC与 4 5例Ⅲ、Ⅳ期卵巢浆液性乳头状癌 (OPSC)的临床和随访资料 ,比较其临床及治疗特点、对一线化疗药物的敏感性及生存时间。结果　EPSPC与OPSC两组的症状、体征、CA12 5水平、无瘤期、复发时间、对一线化疗药物的反应及生存时间差异无统计学意义 ,而EPSPC组的完全缓解率 (2 5 .0 % )与OPSC组 (91.8% )比较 ,显著降低 (P <0 .0 1)。结论　EPSPC与OPSC临床过程类似 ,当治疗手段相同时 ,对一线化疗药物的敏感性及生存时间相近。     

Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases

The rate and clinical features of patients admitted to King George V Hospital with extraovarian peritoneal serous papillary carcinoma during a 9-year period were reviewed. In this time, 31 of 236 (13%) patients with an initial diagnosis of invasive serous ovarian carcinoma fulfilled the surgicopathologic criteria for this entity. All patients had disseminated tumor equivalent to ovarian Stage III and IV disease (International Federation of Gynecology and Obstetrics [FIGO]) and with predominantly high-grade neoplasms. They were managed by surgical exploration, tumor debulking where possible, and postoperative chemotherapy. A comparison with a contemporaneous series of 139 patients with primary epithelial ovarian carcinoma matched for stage and grade of disease and managed similarly showed no difference in actuarial survival. The median survival times were 11.3 months for patients with extraovarian serous papillary carcinomas and 13.5 months for patients with equivalent primary ovarian neoplasms. The features of the disease and the treatment regimens used are discussed.     

Extraovarian peritoneal serous papillary carcinoma showing complete remission after treatment with cisplatin

Extraovarian peritoneal serous papillary carcinoma is a rare disease in women that arises from extraovarian peritoneum with müllerian potential. It shows histopathological findings identical to those of ovarian serous carcinoma. At diagnosis, this disease usually exhibits peritoneal carcinomatosis, but evidence of a primary site is lacking. We experienced a case of extraovarian peritoneal serous papillary carcinoma in a 72-year-old woman who complained of abdominal distension and soon after developed bowel obstruction. Although we failed to perform any effective surgical procedure at laparotomy, because the cancer was extremely advanced, treatment with cisplatin resulted in rapid reduction of the tumor, and, finally, in its complete disappearance. Cisplatin was administered only three times, and the total dose was 300 mg. The patient is still alive and clinically free of recurrence 32 months after her first visit to our hospital. In this report we describe her clinical course, and discuss the diagnosis and treatment of this disease, and the usefulness of tumor markers for monitoring it. Received: February 22, 2000 / Accepted: May 29, 2000     

A case of peritoneal serous papillary carcinoma

A 65-year-old female was admitted to our hospital with abdominal distension. Abdominal CT and MRI revealed massive ascites and an omental cake, but the ovaries were of normal size. After an omentum biopsy was performed during open abdominal surgery, she was diagnosed as peritoneal serous papillary adenocarcinoma. After 6 courses of chemotherapy with paclitaxel and carboplatin, the massive ascites totally disappeared, and a second look operation could be performed. She is still alive with no sign of recurrence.     

子宫乳头状浆液性癌10例临床病理分析

目的 :探讨子宫乳头状浆液性癌 (UPSC)的生物学行为特征与预后关系。方法 :回顾分析 1988年 7月～ 2 0 0 0年 8月临沂市肿瘤医院收治的 10例UPSC的临床病理资料。结果 :术前分期 :I期 9例 ,占 90 % ,Ⅲ期 1例 ,占 10 %。细胞分化 :G14例 ,G2 4例 ,G3 2例。手术 -病理分期 :Ⅰ期 2例 ,占 2 0 % ,Ⅲ期 6例 ,占 6 0 % ,Ⅳ期 2例 ,占 2 0 %。细胞分化 :G3 6例 ,占 6 0 % ;肌层浸润 :浸润超过 1/ 2肌层 7例 ,占 70 %。 2例 (2 0 % )术后 1年内死亡 ,5例 (5 0 % ) 3年内死亡 ,6例 (6 0 % ) 5年内死亡。结论 :UPSC细胞分化差 ,早期易发生深肌层浸润及盆腹腔淋巴结和远处转移 ,预后极差。治疗应采取以手术为主的综合治疗     

Encapsulated papillary carcinoma of the breast: A clinicopathological study of 49 cases

BackgroundEncapsulated papillary carcinoma (EPC) has been considered as a variant of ductal carcinoma in situ (DCIS). Recent studies suggest that EPC could be invasive, as it often lacks myoepithelial cells (MECs) at their periphery. The current study was performed to investigate the biological features of EPC.MethodsForty-nine EPC patients admitted to the Tai′an Central Hospital and Qilu Hospital of Shandong University from January 2004 to December 2014 were included in this study. We retrospectively analyzed the clinicopathological findings, the presence and distribution of MECs, as well as the outcomes.ResultsThe mean age at diagnosis was 68.5 years. The mean tumor size was 2.0 cm. MECs were completely absent in all the 49 cases, Most tumors were estrogen receptor (ER) and progesterone receptor (PR) positive (95.9%). HER2 1+ immunoreactivity was seen in only 8 cases. Twenty-five patients underwent lumpectomy and twenty-four underwent mastectomy. Thirty-nine received evaluation of lymph node, and three (7.7%) patients had lymph node involvement. Follow-up information was available in 29 patients (8 to 104 months, mean 47 months), among which 5 developed local recurrences and 2 distant metastases.ConclusionEPC is an indolent invasive carcinoma with biological features between in DCIS and invasive carcinoma, with predominance of the latter. EPC rarely showed lymph node involvement and was characterized by favorable prognosis. EPC can be treated with adequate local therapy and hormonal therapy, whereas, the benefit of radiation after lumpectomy remains uncertain.